RYALTRIS Drug Patent Profile
✉ Email this page to a colleague
When do Ryaltris patents expire, and what generic alternatives are available?
Ryaltris is a drug marketed by Glenmark Specialty and is included in one NDA. There are fourteen patents protecting this drug.
This drug has eighty-eight patent family members in thirty-two countries.
The generic ingredient in RYALTRIS is mometasone furoate; olopatadine hydrochloride. There are thirty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the mometasone furoate; olopatadine hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Ryaltris
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 13, 2025. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RYALTRIS?
- What are the global sales for RYALTRIS?
- What is Average Wholesale Price for RYALTRIS?
Summary for RYALTRIS
International Patents: | 88 |
US Patents: | 14 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Drug Prices: | Drug price information for RYALTRIS |
What excipients (inactive ingredients) are in RYALTRIS? | RYALTRIS excipients list |
DailyMed Link: | RYALTRIS at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RYALTRIS
Generic Entry Date for RYALTRIS*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT NDA:
Dosage:
SPRAY, METERED;NASAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for RYALTRIS
Drug Class | Corticosteroid Histamine-1 Receptor Antagonist Histamine-1 Receptor Inhibitor Mast Cell Stabilizer |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists Histamine H1 Receptor Antagonists |
Physiological Effect | Decreased Histamine Release |
US Patents and Regulatory Information for RYALTRIS
RYALTRIS is protected by fourteen US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of RYALTRIS is ⤷ Sign Up.
This potential generic entry date is based on NEW PRODUCT.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting RYALTRIS
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A PEDIATRIC PATIENT
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF DELIVERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A NASAL AIRWAY
Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE
Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting RYALTRIS
NEW PRODUCT
Exclusivity Expiration: ⤷ Sign Up
International Patents for RYALTRIS
See the table below for patents covering RYALTRIS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Taiwan | 201927359 | Dispensing device and pharmaceutical composition for the treatment of rhinitis | ⤷ Sign Up |
Slovenia | 3043773 | ⤷ Sign Up | |
Eurasian Patent Organization | 201892321 | ДОЗИРУЮЩЕЕ УСТРОЙСТВО И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ РИНИТА | ⤷ Sign Up |
Japan | 6203967 | ⤷ Sign Up | |
Russian Federation | 2015128497 | СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С ФИКСИРОВАННОЙ ДОЗОЙ, СОДЕРЖАЩАЯ МОМЕТАЗОН И ОЛОПАТАДИН | ⤷ Sign Up |
Mexico | 2018015739 | DISPOSITIVO DISPENSADOR Y COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE LA RINITIS. (DISPENSING DEVICE AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RHINITIS.) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RYALTRIS
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3043773 | 301154 | Netherlands | ⤷ Sign Up | PRODUCT NAME: MOMETASON OF EEN ZOUT DAARVAN EN OLOPATADINE OF EEN ZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 126186 20211014; FIRST REGISTRATION: AT 140638 20210426 |
3043773 | 2190041-0 | Sweden | ⤷ Sign Up | PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; NAT. REG. NO/DATE: MT NR 60226 20210519; FIRST REG.: AT APPROVAL NR 140638 20210426 |
3043773 | C202130060 | Spain | ⤷ Sign Up | PRODUCT NAME: MOMETASONA O UNA SAL DE LA MISMA Y OLOPATADINA O UNA SAL DE LA MISMA; NATIONAL AUTHORISATION NUMBER: 86059-SE/H/2040/001/DC; DATE OF AUTHORISATION: 20210701; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 140638; DATE OF FIRST AUTHORISATION IN EEA: 20210419 |
3043773 | 21C1057 | France | ⤷ Sign Up | PRODUCT NAME: MOMETASONE OU L'UN DE SES SELS AVEC OLOPATADINE OU L'UN DE SES SELS; NAT. REGISTRATION NO/DATE: NL52121 20211026; FIRST REGISTRATION: AT - 140638 20210426 |
0548114 | SPC/GB97/064 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MOMETASONE FUROATE MONOHYDRATE; REGISTERED: FR AMM 343012.6 19970219; UK 00201/0216 19970410 |
3043773 | 122021000085 | Germany | ⤷ Sign Up | PRODUCT NAME: MOMETASON ODER EIN SALZ DAVON UND OLOPATADIN ODER EIN SALZ DAVON; NAT. REGISTRATION NO/DATE: 2205824.00.00 20211117; FIRST REGISTRATION: OESTERREICH 140638 20210426 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |